Nevertheless, the recent observation that PD-L1 and PD-L2 are expressed in EBV-positive, but not EBV-negative, gastric carcinomas suggests that PD-1/CTLA-4 blockade may be therapeutically useful even for EBV-positive cancers with the less immunogenic forms of viral latency. This evidence concerns the gene PDCD1LG2 and gastric carcinoma.